Nivolumab (Opdivo®), a PD-L1 inhibitor, was approved by the Food and Drug Administration (FDA) [27], when studies demonstrated that Nivolumab, associated with a CTLA-4 blocker (Ipilimumab) or in monotherapy, generated increased overall survival when compared to docetaxel in patients with metastatic NSCLC of squamous etiology who had already failed to respond to platinum-based systemic treatment [28,29,30]. Here, CTLA4 is linked to non-small cell lung carcinoma.